Fineline Cube

Follow:
14691 Articles
Novartis' Cosentyx Wins Positive CHMP Opinion for Polymyalgia Rheumatica – IL‑17A Blockade Poised to Enter Steroid-Dependent Rheumatology
CompanyDrug

Novartis’ Cosentyx Wins Positive CHMP Opinion for Polymyalgia Rheumatica – IL‑17A Blockade Poised to Enter Steroid-Dependent Rheumatology

Eli Lilly Wins Full FDA Approval for Inluriyo–Verzenio Combination – Oral Regimen Doubles Median Progression-Free Survival in ESR1-Mutated Metastatic Breast Cancer
CompanyDrug

Eli Lilly Wins Full FDA Approval for Inluriyo–Verzenio Combination – Oral Regimen Doubles Median Progression-Free Survival in ESR1-Mutated Metastatic Breast Cancer

FDA Accepts Alexion's BLA for Efzimfotase Alfa With Priority Review – Potential Twice‑Monthly Enzyme Replacement Therapy for Hypophosphatasia (HPP) Patients Aged 2+
CompanyDrug

FDA Accepts Alexion’s BLA for Efzimfotase Alfa With Priority Review – Potential Twice‑Monthly Enzyme Replacement Therapy for Hypophosphatasia (HPP) Patients Aged 2+

Nuvation Bio Secures FDA sNDA Approval for IBTROZI® (Taletrectinib) – Updated Label Reports Longest Median DOR Among Approved ROS1 TKIs in TKI‑Naïve ROS1‑Positive NSCLC
CompanyDrug

Nuvation Bio Secures FDA sNDA Approval for IBTROZI® (Taletrectinib) – Updated Label Reports Longest Median DOR Among Approved ROS1 TKIs in TKI‑Naïve ROS1‑Positive NSCLC

MIIT and Nine Departments Issue China's "15th Five‑Year Plan for Pharmaceutical Industry Development" – Innovative Drug Sector Targeted to Grow Over 20 % Annually Through 2030
Policy / Regulatory

MIIT and Nine Departments Issue China’s “15th Five‑Year Plan for Pharmaceutical Industry Development” – Innovative Drug Sector Targeted to Grow Over 20 % Annually Through 2030

Roche Opens Genentech Innovation Center Boston at Harvard's Enterprise Research Campus – New US Hub for Cardiovascular, Renal and Metabolism R&D
Company

Roche Opens Genentech Innovation Center Boston at Harvard’s Enterprise Research Campus – New US Hub for Cardiovascular, Renal and Metabolism R&D

Medinno Pharmaceutical Closes Over RMB 200 Million Series A Led by Sunshine Ronghui Capital – MDI‑1228, World's First Topical Pan‑JAK/Pan‑Trk Inhibitor, Advances Global Clinical Development
CompanyDeals

Medinno Pharmaceutical Closes Over RMB 200 Million Series A Led by Sunshine Ronghui Capital – MDI‑1228, World’s First Topical Pan‑JAK/Pan‑Trk Inhibitor, Advances Global Clinical Development

Qiantang Longyue Closes Over RMB 100 Million A++ Round Led by Huimei Capital – Drug Delivery Systems Platform Nears Unicorn Status
CompanyDeals

Qiantang Longyue Closes Over RMB 100 Million A++ Round Led by Huimei Capital – Drug Delivery Systems Platform Nears Unicorn Status

TransThera Sciences' YOCHANRA (Tinengotinib) Receives First Prescription in China – World's First Approved Targeted Therapy for Post‑FGFR‑Inhibitor Cholangiocarcinoma
CompanyDrug

TransThera Sciences’ YOCHANRA (Tinengotinib) Receives First Prescription in China – World’s First Approved Targeted Therapy for Post‑FGFR‑Inhibitor Cholangiocarcinoma

XtalPi's LCC Technologies Signs Drug Discovery Collaboration with Stanford University – Chiral Chemistry Meets Disease Biology
Others

XtalPi’s LCC Technologies Signs Drug Discovery Collaboration with Stanford University – Chiral Chemistry Meets Disease Biology

Huadong Medicine's Sinclair Secures Exclusive China Collaboration for Maybio's iPSC‑Engineered MB007 ECM Collagen – Regenerative Aesthetics Bet
CompanyDeals

Huadong Medicine’s Sinclair Secures Exclusive China Collaboration for Maybio’s iPSC‑Engineered MB007 ECM Collagen – Regenerative Aesthetics Bet

WuXi XDC Licenses WuXiTecan‑2 Payload‑Linker Technology to Ona Therapeutics – Exclusive Global ADC Deal Deepens Partnership
CompanyDeals

WuXi XDC Licenses WuXiTecan‑2 Payload‑Linker Technology to Ona Therapeutics – Exclusive Global ADC Deal Deepens Partnership